OpenEvidence partners with Penn Medicine on clinical AI — including Botswana

OpenEvidence and Penn Medicine announced a partnership to bring OpenEvidence’s AI clinical decision support to more than 10,000 clinicians across Penn’s seven-hospital U.S. system, and to design tools with the Botswana-UPenn Partnership for care in lower-resource settings.

Same-day HEALTH primary that a widely used physician AI is wiring into a major academic health system and explicitly planning tools for lower-resource global health, not just another U.S. pilot press release.

OpenEvidence and Penn Medicine announced a global partnership on 15 Sep 2026. The company page, titled “OpenEvidence and Penn Medicine Partner to Advance Medical Intelligence for Global Health,” is dated September 15, 2026, and datelined MIAMI, FL & PHILADELPHIA, PA. Clinical decision support here means software that helps a doctor find evidence or next-step options for a patient. That company PRIMARY is the filing event. These are company claims. This desk did not sit inside Penn’s hospitals.

Scope, as OpenEvidence tells it: deploy OpenEvidence to clinicians at Penn Medicine — more than 10,000 clinicians across seven U.S. hospitals. File that clinician count and seven-hospital system as OpenEvidence’s. This desk did not count the clinicians.

Also, still company: that clinical decision support will extend to low- and middle-income settings through the Botswana-UPenn Partnership, or BUP. The company says the agreement lets Penn Medicine teams design a tool from the ground up for the conditions of practicing in the region, working with local partners rather than only exporting a U.S. interface. File that design-with-local-partners frame as OpenEvidence’s. This desk is not inventing a Botswana go-live date, a country-wide rollout, or a dollar value.

Product framing, company: OpenEvidence’s tools will be accessible to clinicians within Penn Medicine campuses and the Botswana-UPenn Partnership, bringing personalized, evidence-based insights drawn from medical literature and from the electronic health record — the digital patient chart — embedded in workflow. The company line is “the right evidence, for the right patient, at the exact right time.” File that job as OpenEvidence’s. This is assist software, not a diagnosis on its own and not FDA clearance for this partnership.

Named voices on the company page: Travis Zack, MD, PhD, chief medical officer at OpenEvidence; Srinath Adusumalli, MD, vice president and chief health information officer at Penn Medicine; and Farouk Dako, MD, MPH, director of the Botswana-UPenn Partnership. File the names and titles as the company’s. Their quotes are color only and stay in Sources.

Company claim on usage — attribute, do not independently certify: OpenEvidence calls itself the most widely used medical AI and clinical decision-making tool among U.S. physicians, and says independent studies find more American physicians use OpenEvidence than all other AI platforms combined. File those “most widely used” lines as OpenEvidence’s. This desk did not run those studies and is not inventing study names the page does not print.

Company about-box on the same page: OpenEvidence is free for verified U.S. clinicians. File that as OpenEvidence’s. This desk did not verify a clinician account.

BUP context, still company via the same page: the Botswana-UPenn Partnership is described as a 25-year academic health partnership in sub-Saharan Africa, working with the University of Botswana and Botswana’s Ministry of Health. Penn Medicine says it has worked in Botswana since 2001. File those lines as the company’s. This desk did not audit the partnership.

Plain English for the rest of the card: clinical decision support = software that helps a doctor find evidence or next-step options for a patient. EHR = electronic health record, the digital patient chart. Botswana-UPenn Partnership = long-running Penn Medicine collaboration with Botswana’s health system and the University of Botswana. low- and middle-income settings = health systems with fewer staff, devices, and dollars than a U.S. academic hospital.

PRIMARY here: OpenEvidence’s 15 Sep 2026 company announcement — Tier A PRIMARY company source, the original record. The company site is product-home context, not a second originating newsroom. The global partnership, the more-than-10,000-clinician / seven-hospital Penn deploy, the Botswana-UPenn design-a-tool frame, the literature-plus-EHR / “right evidence… right time” workflow line, the Zack / Adusumalli / Dako names, the “most widely used” usage claim, the free-for-verified-U.S.-clinicians about-box, and the 25-year / since-2001 BUP lines are company-attributed. Usage claims stay company-attributed. NOT claimed: FDA De Novo or 510(k) for this partnership, a contract dollar value, exclusivity, a Botswana go-live date or country-wide rollout, independently verified physician-usage counts or named studies, that this desk tested OpenEvidence inside Penn, a stock tip, or investment advice. Distinct from the already-filed microstructure-imaging-micsi-pet-fda, kairon-health-5m, powerful-medical-queen-of-hearts-fda-de-novo, azmed-azchest-fda-6th, evvy-40m-series-b, mithrl-20m-series-a, nvidia-chop-cardiac-monai, and unc-openai-foundation-40m-cancer-vaccines.